Renal Transplantation in Hepatitis C Positive Patients: A Single Centre Experience

Table 2

Results.

Patients (𝑛=211)	Group A (𝑛=132)	Group B (𝑛=79)	𝑃 value
Study period	Jan 99–Dec 06	Jan 98–Dec 06
Mean followup (years; range)	8.38±2.2 (3.8–11.8)	8.95±2.2 (4–12.6)
Mean SCr (mg/dL) at
1 year	1.38±0.29	1.3±0.37	NS
3 years	1.55±0.34	1.58±0.64	NS
5 years	1.72±0.47	1.75±0.61	NS
7 years	1.8±0.39	1.97±0.73	NS
10 years	1.87±0.69	2.1±0.81	NS
Predominant biopsy findings—percentage
Acute rejection episodes—percentage
Bcell mediated	8.3 (𝑛=11)	15.2 (𝑛=12)	NS
Tcell mediated	8.3 (𝑛=11)	17.7 (𝑛=14)	0.03
Suspicious T/B	9.8/0 (𝑛=13/0)	20.2/5 (𝑛=16/4)	0.024/0.022
Acute CNI toxicity	12.1 (𝑛=16)	19 (𝑛=15)	NS
Recurrence	1.5 (𝑛=2)	2.5 (𝑛=2)	NS
Chronic rejections
Bcell mediated	3 (𝑛=4)	6.3 (𝑛=5)	NS
Tcell mediated	3.8 (𝑛=5)	11.4 (𝑛=9)	0.029
IFTA	8.3 (𝑛=11)	19 (𝑛=15)	0.018
Chronic CNI toxicity	9.1 (𝑛=12)	16.5 (𝑛=13)	NS
Recurrence	2.3 (𝑛=3) (ATIN)	3.8 (𝑛=2 (ATIN), 𝑛=1 (MPGN))	NS
De novo nephropathy	1 (MN)	0	NS
Chronic liver failure dueto reactivation	22 (𝑛=29)	31 (𝑛=25)	𝑃=0.0002

Abbreviations: CNI: calcineurin inhibitor; CGN: chronic glomerulonephritis; CsA: cyclosporin A; ELISA: enzyme linked immunoassay; ESRD: end-stage renal disease; G-CSF: granulocyte colony stimulating factor; HCV: hepatitis C virus; IFTA: unexplained interstitial fibrosis and tubular atrophy; LCM: lymphocyte cross-matching; PBSC: peripheral blood stem cells; POD: postoperative day; RTx: renal transplantation; SCr: serum creatinine; TIP: tolerance induction protocol.